The Prioritisation and Risk Evaluation of Medicines in the EnviRonment, PREMIER project, aims to deliver a novel assessment system for characterising the environmental risks of APIs, and which can be used to:

Screen and prioritise legacy APIs for a tailored environmental assessment

Identify potential hazards associated with APIs in development and explore the options to steer the design process in a greener direction

Make relevant environmental data on APIs more visible and accessible to all stakeholders


Radboud University NijmegenNL
University of YorkUK
ECT Oekotoxikologie GmbHDE
Rijksinstituut voor Volksgezondheid en MilieuNL
Istituto di Ricerche Farmacologiche Mario NegriIT
Eidgenoessische Anstalt Fuer Wasserversorgung Abwasserreinigung Und GewässerschutzCH
Leuphana Universitat LuneburgDE
University of ExeterUK
Teamit Research SLSP
Simomics LimitedUK
Fraunhofer Gesellschaft Zur Foerderung der Angewandten Forschung E.V.DE
Helsingin YliopistoFI
Goeteborgs UniversitetSE
AstraZeneca ABSE
GlaxoSmithKline Research and development Ltd.UK
F. Hoffmann-La RocheCH
SANOFI-Aventis Recherche & DeveloppementFR
Institute de Recherches Internationales SERVIERFR
Eli Lilly and Company LimitedDE
The European Medicines AgencyNL
Merck Sharp & Dohme CorpUS


Funding period: 01/09/2020 to 30/08/2026. Years: 6 (2020-26)
EFPIA companies: 10. Academic & SMEs: 15
Total Budget: € 9 Million
IMI contribution: € 4.5 Million (in cash). EFPIA contribution: € 4.5 Million (in kind)
Project Coordinator: Radboud University Nijmegen
Project Leader: AstraZeneca AB


“PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 875508. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA”.

About IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences.